JP2013517781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517781A5 JP2013517781A5 JP2012550437A JP2012550437A JP2013517781A5 JP 2013517781 A5 JP2013517781 A5 JP 2013517781A5 JP 2012550437 A JP2012550437 A JP 2012550437A JP 2012550437 A JP2012550437 A JP 2012550437A JP 2013517781 A5 JP2013517781 A5 JP 2013517781A5
- Authority
- JP
- Japan
- Prior art keywords
- fgf23
- composition
- sequence
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 claims 22
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 230000035772 mutation Effects 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 1
- 101001139093 Homo sapiens Klotho Proteins 0.000 claims 1
- 102100020686 Klotho Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000865 phosphorylative effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/696,693 | 2010-01-29 | ||
| US12/696,693 US8420088B2 (en) | 2008-01-28 | 2010-01-29 | Methods and compositions using FGF23 fusion polypeptides |
| PCT/EP2011/051112 WO2011092234A1 (en) | 2010-01-29 | 2011-01-27 | Methods and compositions using fgf23 fusion polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016087432A Division JP2016190847A (ja) | 2010-01-29 | 2016-04-25 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517781A JP2013517781A (ja) | 2013-05-20 |
| JP2013517781A5 true JP2013517781A5 (OSRAM) | 2014-01-16 |
| JP5964243B2 JP5964243B2 (ja) | 2016-08-03 |
Family
ID=43828141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550437A Expired - Fee Related JP5964243B2 (ja) | 2010-01-29 | 2011-01-27 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
| JP2016087432A Pending JP2016190847A (ja) | 2010-01-29 | 2016-04-25 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016087432A Pending JP2016190847A (ja) | 2010-01-29 | 2016-04-25 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8420088B2 (OSRAM) |
| EP (2) | EP3124612A1 (OSRAM) |
| JP (2) | JP5964243B2 (OSRAM) |
| KR (1) | KR20130032296A (OSRAM) |
| CN (3) | CN103204941B (OSRAM) |
| AR (1) | AR080043A1 (OSRAM) |
| AU (1) | AU2011209380B2 (OSRAM) |
| CA (1) | CA2787285A1 (OSRAM) |
| EA (1) | EA201201047A1 (OSRAM) |
| ES (1) | ES2605302T3 (OSRAM) |
| MX (1) | MX336391B (OSRAM) |
| PL (1) | PL2529016T3 (OSRAM) |
| PT (1) | PT2529016T (OSRAM) |
| TW (2) | TWI569805B (OSRAM) |
| UY (1) | UY33204A (OSRAM) |
| WO (1) | WO2011092234A1 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| ES2748038T3 (es) | 2011-07-01 | 2020-03-12 | Ngm Biopharmaceuticals Inc | Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP2925775B1 (en) | 2012-11-28 | 2020-09-16 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| CN102961739A (zh) * | 2012-12-12 | 2013-03-13 | 黄曙 | Klotho蛋白的用途 |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| EP2938740B1 (en) | 2012-12-27 | 2022-04-20 | NGM Biopharmaceuticals, Inc. | Chimeric fgf19 peptides for use in treating bile acid disorders |
| WO2014152993A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Regents Of The University Of Oklahoma | Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions |
| KR101492710B1 (ko) * | 2013-04-03 | 2015-02-13 | 중앙대학교 산학협력단 | Fgf23 유전자를 이용한 전립선암 진단용 마커 및 이를 이용한 전립선암 예측 및 진단 방법 |
| ES2714127T3 (es) | 2013-10-24 | 2019-05-27 | Tokyo Metropolitan Geriatric Hospital And Inst Of Gerontology | Células madre musculares o mioblastos, procedimiento de cribado de sustancias que participan en la conversión metabólica usando las mismas, y composición farmacéutica que comprende la sustancia obtenida de dicho procedimiento del cribado |
| KR102178945B1 (ko) | 2013-10-28 | 2020-11-13 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 암 모델 및 관련 방법 |
| US20150140036A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Institutes For Biomedical Research, Inc. | Low, immune enhancing, dose mtor inhibitors and uses thereof |
| PE20170256A1 (es) | 2014-01-24 | 2017-04-22 | Ngm Biopharmaceuticals Inc | Proteinas de union y sus metodos de uso |
| JP6370577B2 (ja) * | 2014-03-26 | 2018-08-08 | 国立大学法人京都工芸繊維大学 | 抗老化物質のスクリーニング方法 |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| KR20170084332A (ko) * | 2014-12-04 | 2017-07-19 | 노파르티스 아게 | Klotho 변이체 폴리펩티드를 사용하는 방법 및 조성물 |
| AU2016215080B2 (en) | 2015-02-06 | 2020-12-24 | The Regents Of The University Of California | Methods and compositions for improved cognition |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| ES2871036T3 (es) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
| EP3464608A4 (en) * | 2016-06-02 | 2020-01-29 | Klotho Therapeutics, Inc. | THERAPEUTIC RECOMBINANT KLOTHO PROTEINS, COMPOSITIONS AND METHODS THEREFOR |
| EA037848B1 (ru) * | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты) |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN107759697B (zh) * | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN113692411A (zh) * | 2019-04-19 | 2021-11-23 | 吉尼松公司 | 成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗 |
| WO2021128065A1 (zh) * | 2019-12-25 | 2021-07-01 | 广州菲康生物技术有限公司 | 人fgf-23的荧光免疫层析试纸和人fgf-23的荧光免疫层析检测试剂盒 |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| US20250154487A1 (en) * | 2023-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Engineered alpha klotho polypeptides and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| US5541094A (en) * | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
| CA2230494A1 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
| US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
| WO1997033572A1 (en) | 1996-03-15 | 1997-09-18 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
| KR20000062345A (ko) | 1996-12-26 | 2000-10-25 | 히라타 다다시 | 신규 폴리펩타이드, 신규 ｄｎａ 및 신규 항체 |
| US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| US6518069B1 (en) | 1999-04-22 | 2003-02-11 | Liposcience, Inc. | Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disorders |
| WO2001012851A2 (en) | 1999-08-12 | 2001-02-22 | Wisconsin Alumni Research Foundation | Identification of genetic markers of biological age and metabolism |
| US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US6406853B1 (en) | 1999-12-23 | 2002-06-18 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
| US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| JP2006238894A (ja) * | 2000-02-15 | 2006-09-14 | Amgen Inc | 線維芽細胞成長因子−２３分子およびその使用 |
| EP1261638A2 (en) | 2000-03-08 | 2002-12-04 | Chiron Corporation | Human fgf-23 gene and gene expression products |
| EP2184296A1 (en) * | 2000-07-19 | 2010-05-12 | Advanced Research And Technology Institute, Inc. | Fibroblast growth factor (fgf23) and methods for use |
| WO2002061046A2 (en) | 2001-01-30 | 2002-08-08 | Regeneron Pharmaceuticals, Inc. | Novel nucleic acid and polypeptide molecules |
| US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
| AU2002302581A1 (en) * | 2001-04-26 | 2002-11-11 | Geneprot, Inc. | Human fibroblast growth factor-related compositions |
| EP1327443A1 (en) | 2001-12-21 | 2003-07-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein |
| US20050004348A1 (en) * | 2002-12-23 | 2005-01-06 | Miyamoto Ken-Ichi | Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| WO2009117622A2 (en) * | 2008-03-19 | 2009-09-24 | Ambrx, Inc. | Modified fgf-23 polypeptides and their uses |
| EA201990619A1 (ru) | 2008-10-10 | 2019-07-31 | Амген Инк. | Fgf21 мутанты и их применение |
| US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
-
2010
- 2010-01-29 US US12/696,693 patent/US8420088B2/en not_active Expired - Fee Related
-
2011
- 2011-01-27 EA EA201201047A patent/EA201201047A1/ru unknown
- 2011-01-27 CN CN201310049110.2A patent/CN103204941B/zh active Active
- 2011-01-27 CN CN201610245160.1A patent/CN105968208A/zh not_active Withdrawn
- 2011-01-27 EP EP16184724.9A patent/EP3124612A1/en not_active Withdrawn
- 2011-01-27 PL PL11705830T patent/PL2529016T3/pl unknown
- 2011-01-27 PT PT117058305T patent/PT2529016T/pt unknown
- 2011-01-27 ES ES11705830.5T patent/ES2605302T3/es active Active
- 2011-01-27 UY UY0001033204A patent/UY33204A/es not_active Application Discontinuation
- 2011-01-27 MX MX2012008780A patent/MX336391B/es unknown
- 2011-01-27 KR KR1020127022498A patent/KR20130032296A/ko not_active Withdrawn
- 2011-01-27 AR ARP110100273A patent/AR080043A1/es unknown
- 2011-01-27 CA CA2787285A patent/CA2787285A1/en not_active Withdrawn
- 2011-01-27 AU AU2011209380A patent/AU2011209380B2/en not_active Ceased
- 2011-01-27 CN CN201180007622.1A patent/CN102725413B/zh active Active
- 2011-01-27 WO PCT/EP2011/051112 patent/WO2011092234A1/en not_active Ceased
- 2011-01-27 EP EP11705830.5A patent/EP2529016B1/en active Active
- 2011-01-27 JP JP2012550437A patent/JP5964243B2/ja not_active Expired - Fee Related
- 2011-01-28 TW TW103100421A patent/TWI569805B/zh not_active IP Right Cessation
- 2011-01-28 TW TW100103508A patent/TWI430805B/zh active
-
2013
- 2013-03-12 US US13/796,711 patent/US8932589B2/en not_active Expired - Fee Related
-
2014
- 2014-11-03 US US14/531,620 patent/US9475857B2/en active Active
-
2016
- 2016-04-25 JP JP2016087432A patent/JP2016190847A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517781A5 (OSRAM) | ||
| Yamazaki et al. | Snake venom Vascular Endothelial Growth Factors (VEGF-Fs) exclusively vary their structures and functions among species | |
| JP2022043042A5 (OSRAM) | ||
| JP6110318B2 (ja) | 線維芽細胞増殖因子の熱安定性変異体 | |
| TW201129373A (en) | Methods and compositions using FGF23 fusion polypeptides | |
| JP2017018125A5 (OSRAM) | ||
| KR102483242B1 (ko) | Mg53 돌연변이체, 및 그의 제조 방법 및 그의 용도 | |
| JP2010534486A5 (OSRAM) | ||
| JP2007289200A5 (OSRAM) | ||
| WO2008038287A3 (en) | N-terminal fgf variants having increased receptor selectivity and uses thereof | |
| JP2015532654A5 (OSRAM) | ||
| JP2017500035A5 (OSRAM) | ||
| JP2013537400A5 (OSRAM) | ||
| WO2008022759A3 (en) | Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase | |
| RU2014122609A (ru) | Модифицированная константная область антитела | |
| JP2010529860A5 (OSRAM) | ||
| CN105246503A (zh) | Pcsk9的新颖结合蛋白 | |
| Fujisawa et al. | Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region | |
| Gasparian et al. | Overexpression in Escherichia coli and purification of human fibroblast growth factor (FGF-2) | |
| JP2016503434A5 (OSRAM) | ||
| JP2008521795A5 (OSRAM) | ||
| US11746134B2 (en) | Human FGF21 mutant with improved effectiveness and stability and pharmaceutical composition thereof | |
| JP2002509691A (ja) | 生物学的活性が改変された組換えタンパク質多量体の製造及び使用 | |
| CN116075524A (zh) | 转铁蛋白受体结合蛋白 | |
| JPWO2020160514A5 (OSRAM) |